Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: Identification of the antigens mediating response

Annals of Surgery

Volumn 228, Issue 3, 1998, Pages 307-319

  Rosenberg, Steven A ^a   Yang, James C ^a   White, Donald E ^a   Steinberg, Seth M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 2; TUMOR ANTIGEN;

CANCER IMMUNOTHERAPY; CONFERENCE PAPER; DRUG MEGADOSE; FOLLOW UP; HUMAN; KIDNEY CANCER; MAJOR CLINICAL STUDY; MELANOMA; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; TUMOR ASSOCIATED LEUKOCYTE; TUMOR REGRESSION;

ADOLESCENT; ADULT; AGED; CHILD; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERLEUKIN-2; KIDNEY NEOPLASMS; MALE; MELANOMA; MIDDLE AGED; PROGNOSIS; REMISSION INDUCTION; TIME FACTORS;

EID: 0032471712     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000658-199809000-00004     Document Type: Conference Paper

References (11)

1. Atkins MB, Mier JW. Therapeutic applications of interleukin-2. New York: Marcel Dekker, 1993.
2. DeVita VT, Hellman S, Rosenberg SA. Biologic therapy of cancer. Philadelphia: JB Lippincott, 1995.
3. Rosenberg SA. Lotze MT, Muul LM, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer, N Engl J Med 1985; 313:1485-1492.
4. Lotze MT, Chang AE, Seipp CA, et al. High-dose recombinant interleukin-2 in the treatment of patients with disseminated cancer: responses, treatment-related morbidity and histologic findings. JAMA 1986; 256:3117-3124.
5. Rosenberg SA, Yang JC, Topalian SL, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2. JAMA 1994; 271:907-913.
6. Yang JC, Topalian SL, Schwartzentruber D, et al. The use of polyethylene glycol-modified interleukin-2 (PEG-IL2) in the treatment of patients with metastatic renal cell carcinoma and melanoma: a phase I study and a randomized prospective study comparing IL-2 alone versus IL-2 combined with PEG-IL-2. Cancer 1995; 76:687-694.
7. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988; 75:800-802.
8. Press SG, Wilson S. Choosing between logistic regression and discriminant analysis. J Am Stat Assoc 1978; 73:699-705.
9. Muul LM, Spiess PJ, Director EP, et al. Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J Immunol 1987; 138:989-995.
10. Topalian SL, Solomon D, Rosenberg SA. Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J Immunol 1989; 142: 3714-3725.
11. Rosenberg SA, Yannelli JR, Yang JC, et al. Treatment of patients with metastatic melanoma using autologous tumor-infiltrating lymphocytes and interleukin-2. J Natl Cancer Inst 1994; 86:1159-1166.